AngioDynamics (NSDQ:ANGO) said today that it inked a non-binding deal with EmboMedics that would see it make a strategic investment in the resorbable microsphere maker, in return for exclusive licensing rights and a potential buyout down the line.
Latham, N.Y.-based AngioDynamics said it signed the letter of intent in January with Maple Grove, Minn.-based EmboMedics, which is developing a resorbable embolic microsphere called the ResoSphere.
The deal would see AngioDynamics buy aan equity stake in EmboMedics, in return for the exclusive license and the right of 1st refusal on EmboMedics' next-generation embolization technology, according to a regulatory filing.
Help employers find you! Check out all the jobs and post your resume.
Latham, N.Y.-based AngioDynamics said it signed the letter of intent in January with Maple Grove, Minn.-based EmboMedics, which is developing a resorbable embolic microsphere called the ResoSphere.
The deal would see AngioDynamics buy aan equity stake in EmboMedics, in return for the exclusive license and the right of 1st refusal on EmboMedics' next-generation embolization technology, according to a regulatory filing.
Help employers find you! Check out all the jobs and post your resume.
